前列地尔联合倍他司汀治疗椎-基底动脉供血不足的临床疗效
|
摘要
目的探讨前列地尔联合倍他司汀治疗椎-基底动脉供血不足的临床疗效。方法随机选取南方医科大学深圳医院2016年1月至2017年5月期间收治的椎-基底动脉供血不足患者,抽取80例纳入研究,用随机数字法分两组,各40例。对照组患者接受前列地尔药物治疗,研究组患者接受倍他司汀联合前列地尔药物治疗,观察两组患者的治疗状况、血流速度等,并对比分析。结果研究组治疗总疗效为92.5%,高于对照组的72.5%,组间数据差异有统计学意义(P<0.05)。对比两组患者血流速度,治疗前组间数据比较差异无统计学意义(P>0.05),治疗后研究组高于对照组,差异有统计学意义(P<0.05);对比两组患者纤维蛋白原、D-二聚体,治疗前组间数据比较差异无统计学意义(P>0.05),治疗后研究组低于对照组,差异有统计学意义(P<0.05);对比血脂指数,包含HDL-C、LDL-C、TG、TC等,治疗前组间数据比较差异无统计学意义(P>0.05),治疗后研究组各指标均优于对照组,差异均有统计学意义(均P<0.05)。结论临床治疗椎-基底动脉供血不足患者可以考虑给予前列地尔联合倍他司汀药物治疗,其疗效突出,能明显改善纤维蛋白原、D-二聚体以及血脂指数。
Objective To analyze and discuss the clinical effects of Alprostadil combined with duloxetine in treatment of vertebrobasilar.Methods 80 cases of patients with vertebrobasilar insufficiency and who accepted treatments in Shenzhen Hospital of Southern Medical University from January,2016 to May,2017 were randomly selected and included in the discussion,and were randomly divided into two groups,with 40 cases in each group.The control group were received the duloxetine treatment,while the study group were treated with Alprostadil combined with alprostadil.Then,the treatment condition and blood flow velocity were observed and compared.Results The total clinical effect in the study group was 92.5%,which was higher than that in the control group of 72.5%,and the data between the two groups were statistically significant(P<0.05).The mean velocity of the vertebrobasilar artery were compared between the two groups,and there was no significant difference between the two groups before treatment(P>0.05);After the treatment, the study group was higher than the control group, the data between the two groups were statistically significant(P<0.05).The fibrinogen and D-dimer of two groups of patients were compared. There was no significant difference between the two groups before treatment(P>0.05);After the treatment, the study group was lower than the control group,the data between the two groups were statistically significant(P<0.05).The blood lipid index were compared,including the HDL-C,LDL-C,TG,TC and so on.Before the treatment,there was no significant difference between the two groups(P>0.05);After the treatment,the study group was better than the control group, the data between the two groups were statistically significant(P<0.05).Conclusion The clinical treatment ofvertebrobasilar insufficiency can be considered the Alprostadil combined with duloxetine,which the clinical effect is prominent,and can improve the velocity of vertebrobasilar artery flow.
Objective To analyze and discuss the clinical effects of Alprostadil combined with duloxetine in treatment of vertebrobasilar.Methods 80 cases of patients with vertebrobasilar insufficiency and who accepted treatments in Shenzhen Hospital of Southern Medical University from January,2016 to May,2017 were randomly selected and included in the discussion,and were randomly divided into two groups,with 40 cases in each group.The control group were received the duloxetine treatment,while the study group were treated with Alprostadil combined with alprostadil.Then,the treatment condition and blood flow velocity were observed and compared.Results The total clinical effect in the study group was 92.5%,which was higher than that in the control group of 72.5%,and the data between the two groups were statistically significant(P<0.05).The mean velocity of the vertebrobasilar artery were compared between the two groups,and there was no significant difference between the two groups before treatment(P>0.05);After the treatment, the study group was higher than the control group, the data between the two groups were statistically significant(P<0.05).The fibrinogen and D-dimer of two groups of patients were compared. There was no significant difference between the two groups before treatment(P>0.05);After the treatment, the study group was lower than the control group,the data between the two groups were statistically significant(P<0.05).The blood lipid index were compared,including the HDL-C,LDL-C,TG,TC and so on.Before the treatment,there was no significant difference between the two groups(P>0.05);After the treatment,the study group was better than the control group, the data between the two groups were statistically significant(P<0.05).Conclusion The clinical treatment ofvertebrobasilar insufficiency can be considered the Alprostadil combined with duloxetine,which the clinical effect is prominent,and can improve the velocity of vertebrobasilar artery flow.
引文
[1]王德发,聂志红,高鹤,等.倍他司汀片联合桂哌齐特针治疗椎-基底动脉供血不足性眩晕[J].中国社区医师,2014,30(1):45-46.
[2]王新德.神经病学[M].北京:人民军医出版社,2001:176-182.
[3]林色永.疏血通联合盐酸倍他司汀治疗脑血栓椎-基底动脉系统供血不足的疗效研究[J].临床医学工程,2017,24(2):215-216.
[4]王宁忻.加味半夏白术天麻汤联合盐酸倍他司汀治疗椎-基底动脉供血不足性眩晕临床体会[J].内蒙古中医药,2016,35(2):89-90.
[5]娄志军.血塞通联合天麻素注射液治疗椎-基底动脉供血不足性眩晕临床观察[J].临床合理用药杂志,2014,7(13):26.
[6]钱芳.健脾养胃活血类中药配合西药治疗老年人椎-基底动脉供血不足性眩晕的临床疗效分析[J].系统医学,2016,1(8):22-24.
[7]叶邦梅,潘小娟.加味补阳还五汤联合盐酸倍他司汀治疗椎-基底动脉缺血性眩晕的疗效及对血液流变学指标的影响[J].中国基层医药,2017,24(11):1702-1706.
[8]肖有为,许彩芹,庞燕,等.前列地尔联合倍他司汀治疗椎-基底动脉供血不足的疗效分析[J].临床军医杂志,2011,39(2):244-245.
[2]王新德.神经病学[M].北京:人民军医出版社,2001:176-182.
[3]林色永.疏血通联合盐酸倍他司汀治疗脑血栓椎-基底动脉系统供血不足的疗效研究[J].临床医学工程,2017,24(2):215-216.
[4]王宁忻.加味半夏白术天麻汤联合盐酸倍他司汀治疗椎-基底动脉供血不足性眩晕临床体会[J].内蒙古中医药,2016,35(2):89-90.
[5]娄志军.血塞通联合天麻素注射液治疗椎-基底动脉供血不足性眩晕临床观察[J].临床合理用药杂志,2014,7(13):26.
[6]钱芳.健脾养胃活血类中药配合西药治疗老年人椎-基底动脉供血不足性眩晕的临床疗效分析[J].系统医学,2016,1(8):22-24.
[7]叶邦梅,潘小娟.加味补阳还五汤联合盐酸倍他司汀治疗椎-基底动脉缺血性眩晕的疗效及对血液流变学指标的影响[J].中国基层医药,2017,24(11):1702-1706.
[8]肖有为,许彩芹,庞燕,等.前列地尔联合倍他司汀治疗椎-基底动脉供血不足的疗效分析[J].临床军医杂志,2011,39(2):244-245.